These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2128509)

  • 21. Genomic identification and biochemical characterization of the mammalian polyamine oxidase involved in polyamine back-conversion.
    Vujcic S; Liang P; Diegelman P; Kramer DL; Porter CW
    Biochem J; 2003 Feb; 370(Pt 1):19-28. PubMed ID: 12477380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of milacemide on extracellular and tissue concentrations of dopamine and 5-hydroxytryptamine in rat frontal cortex.
    Semba J; Doheny M; Patsalos PN; Sarna G; Curzon G
    Br J Pharmacol; 1992 Jan; 105(1):59-62. PubMed ID: 1596690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thyroid iodide transport is reduced by administration of monoamine oxidase A inhibitors to rats.
    Cabanillas AM; Masini-Repiso AM; Costamagna ME; Pellizas C; Coleoni AH
    J Endocrinol; 1994 Nov; 143(2):303-8. PubMed ID: 7829993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inactivation of monoamine oxidase B by analogues of the anticonvulsant agent milacemide (2-(n-pentylamino)acetamide).
    Nishimura K; Lu X; Silverman RB
    J Med Chem; 1993 Feb; 36(4):446-8. PubMed ID: 8474100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Species differences in the interactions of the anticonvulsant milacemide and some analogues with monoamine oxidase-B.
    O'Brien EM; Dostert P; Tipton KF
    Biochem Pharmacol; 1995 Jul; 50(3):317-24. PubMed ID: 7646533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potentiation of para-hydroxyamphetamine-induced head-twitch response by inhibition of monoamine oxidase type A in the brain.
    Tadano T; Satoh S; Satoh N; Kisara K; Arai Y; Kim SK; Kinemuchi H
    J Pharmacol Exp Ther; 1989 Jul; 250(1):254-60. PubMed ID: 2501477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effects of chronic administration of inhibitors of flavin and quinone amine oxidases on imidazoline I(1) receptor density in rat whole brain.
    Holt A; Todd KG; Baker GB
    Ann N Y Acad Sci; 2003 Dec; 1009():309-22. PubMed ID: 15028605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine metabolic activity of porcine FAD-containing monooxygenase by selective monoamine oxidase-B inhibitors.
    Wu RF; Ichikawa Y
    FEBS Lett; 1995 Jan; 358(2):145-8. PubMed ID: 7828725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I; Youdim MB; Finberg JP
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnestic rodents.
    Handelmann GE; Nevins ME; Mueller LL; Arnolde SM; Cordi AA
    Pharmacol Biochem Behav; 1989 Dec; 34(4):823-8. PubMed ID: 2516327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The influence of metabolism on the MAO-B inhibitory potency of selegiline.
    Haberle D; Szökõ E; Magyar K
    Curr Med Chem; 2002 Jan; 9(1):47-51. PubMed ID: 11860347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amine oxidases from Aspergillus niger: identification of a novel flavin-dependent enzyme.
    Schilling B; Lerch K
    Biochim Biophys Acta; 1995 Apr; 1243(3):529-37. PubMed ID: 7727530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biotransformation of xenobiotics by amine oxidases.
    Benedetti MS
    Fundam Clin Pharmacol; 2001 Apr; 15(2):75-84. PubMed ID: 11468017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The glycine-prodrug, milacemide, increases the seizure threshold due to hyperbaric oxygen; prevention by 1-deprenyl.
    Youdim MB; Kerem D; Duvdevani Y
    Eur J Pharmacol; 1988 Jun; 150(3):381-4. PubMed ID: 3138141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monoamine oxidase in pancreatic islets, exocrine pancreas, and liver from rats. Characterization with clorgyline, deprenyl, pargyline, tranylcypromine, and amezinium.
    Lenzen S; Nahrstedt H; Panten U
    Naunyn Schmiedebergs Arch Pharmacol; 1983 Nov; 324(3):190-5. PubMed ID: 6419132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different effects of monoamine oxidase inhibition on MPTP depletion of heart and brain catecholamines in mice.
    Fuller RW; Hemrick-Luecke SK; Kindt MV; Heikkila RE
    Life Sci; 1988; 42(3):263-71. PubMed ID: 3121972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties of L-deprenyl and MDL 72145.
    Fozard JR; Zreika M; Robin M; Palfreyman MG
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Nov; 331(2-3):186-93. PubMed ID: 3937059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of haloallylamines on polyamine oxidase activity and spermine levels in Ascaris suum.
    Müller S; Hunter KJ; Walter RD
    Parasitol Res; 1996; 82(6):571-3. PubMed ID: 8832742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The FAD dependent amine oxidases in relation to developmental state of enterocyte.
    Fogel WA; Maslinski C
    J Neural Transm Suppl; 1994; 41():95-9. PubMed ID: 7931271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The polyamine oxidase inactivator MDL 72527.
    Seiler N; Duranton B; Raul F
    Prog Drug Res; 2002; 59():1-40. PubMed ID: 12458962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.